AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 3

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We use our state-of-the-art dedicated workflow for designing focused libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Our library distinguishes itself through several key aspects:

  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

Q9P1Z3

UPID:

HCN3_HUMAN

Alternative names:

-

Alternative UPACC:

Q9P1Z3; D3DV90; Q4VX12; Q8N6W6; Q9BWQ2

Background:

The Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 3, identified by the accession number Q9P1Z3, plays a pivotal role in cellular excitability. This protein functions as a hyperpolarization-activated potassium channel and is known to facilitate the permeation of sodium ions, contributing to the intricate balance of ion flux across cell membranes.

Therapeutic significance:

Understanding the role of Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 3 could open doors to potential therapeutic strategies. Its unique ability to regulate potassium and sodium ion flow makes it a compelling target for drug discovery, aiming to modulate cellular excitability in various physiological and pathological conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.